Related Experiment Videos
Biosynthetic human growth hormone: current status and future questions
R G Thompson1, P Conforti, J Holcombe
1Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, Indiana 46285.
Journal of Endocrinological Investigation
|January 1, 1989
Summary
Biosynthetic human growth hormone (hGH) significantly improves growth velocity in children with growth hormone deficiency. Dosage adjustments may be needed as children approach puberty, and optimal treatment strategies require further investigation.
Area of Science:
- Pediatric endocrinology
- Biotechnology
- Genetics
Background:
- Limited natural human growth hormone (hGH) supplies historically restricted treatment for children with growth hormone deficiency.
- Recombinant DNA technology has enabled the mass production of biosynthetic human growth hormone (somatropin), increasing availability.
Purpose of the Study:
- To evaluate the efficacy and optimal dosing of biosynthetic hGH in children with growth hormone deficiency.
- To assess growth response in relation to age and treatment duration.
Main Methods:
- Longitudinal study of over 200 treatment-naïve children receiving biosynthetic hGH for at least two years.
- A double-blind study comparing two doses (0.06 vs. 0.10 mg/kg thrice weekly) in previously treated children for 12 months.
Main Results:
- Mean growth velocity increased from 3.6 cm/yr to 8.8 cm/yr in the first year and 7.25 cm/yr in the second year.
- Growth response was inversely related to age, mirroring natural growth patterns.
- A higher dose showed greater initial growth but not sustained over 12 months, indicating individual variability.
Conclusions:
- Biosynthetic hGH is effective in improving growth in children with deficiency.
- Individualized dosing is crucial, as higher doses do not guarantee sustained or universal benefits.
- Further research is needed to refine diagnostic criteria, optimal dosing, and long-term treatment protocols.